Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin
- 242 Downloads
External beam radiotherapy (EBRT) after conservative surgery for early breast cancer requires 5–7 weeks. For elderly patients and those distant from an RT center, attending for EBRT may be difficult or impossible. We investigated local toxicity, cosmetic outcomes, and quality of life in a new breast irradiation technique—intraoperative avidination for radionuclide therapy (IART)—in which avidin is administered to the tumor bed and 90Y-labelled biotin later administered intravenously to bind the avidin and provide irradiation. Reduced duration EBRT (40 Gy) is given subsequently.
After surgery, 50 (ten patients), 100 (15 patients) or 150 mg (ten patients) of avidin was injected into the tumor bed. After 12-24 h, 3.7 GBq 90Y-biotin (beta source for therapeutic effect) plus 185 MBq 111In-biotin (gamma source for imaging and dosimetry) was infused slowly. Whole-body scintigraphy and SPECT/CT images were taken for up to 30 h. Shortened EBRT started 4 weeks later. Local toxicity was assessed by RTOG scale; quality of life was assessed by EORTC QOL-30.
Of 35 patients recruited (mean age 63 years; range 42–74) 32 received IART plus EBRT. 100 mg avidin provided 19.5 ± 4.0 Gy to the tumor bed and was considered the optimum dose. No side-effects of avidin or 90Y-biotin occurred, with no hematological or local toxicity. Local G3 toxicity occurred in 3/32 patients during EBRT. IART plus EBRT was well accepted, with good cosmetic outcomes and maintained quality of life.
IART plus reduced EBRT can accelerate irradiation after conservative breast surgery.
KeywordsAvidin Biotin Breast cancer Radiotherapy Molecular radionuclide therapy
This study was supported by grants from the Italian Association for Cancer Research (AIRC). The authors thank Don Ward for help with the English and Deborah Console for editing the manuscript.
Conflicts of interest
G. Paganelli is a consultant to Sigma-Tau SpA. R. De Santis receives salaries from Sigma-Tau SpA. All other authors declared that they have no conflicts of interest.
- 4.Morrow M, Strom EA, Basset LW, Dershaw DD, Fowble B, Giuliano A, et al. American College of Radiology; American College of Surgeons; Society of Surgical Oncology; College of American Pathology. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52:277–300.CrossRefPubMedGoogle Scholar
- 21.Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46:99–106S.Google Scholar
- 25.Chinol M, Ferrari M. Methods to reduce radiation exposure to personnel during radiolabelling and infusion. In: Chinol M, Paganelli G, editors. Radionuclide peptide of cancer therapy. New York, NY: Taylor & Francis Group; 2006. pp. 301–13.Google Scholar
- 30.Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 scoring manual. 2nd ed. Brussels: European Organization for Research and Treatment of Cancer; 1999.Google Scholar
- 33.Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMedGoogle Scholar